OMDA · Omada Health, Inc. · Stock research

Current Thesis

The binary resolved on 2026-08-06 and it resolved in the bulls' favour: Q2 2026 revenue $87.835M, +43% YoY, against $80.190M consensus; EPS $0.08 versus a $(0.01) estimate; adjusted EBITDA $11M against a $(0.2)M loss a year earlier; GAAP net income $5M, the second consecutive GAAP-positive quarter; FY2026 revenue guidance lifted to $334–340M from $322–330M, above the $327.789M the Street carried. What has changed since the 2026-08-15 note is not the fundamentals — no company filing or release has landed since — but the tape. Price closed $23.89 on 2026-08-21 against $24.04 on 2026-08-14 and a 52-week high of $26.78, so the beat-and-raise leg has spent two weeks going sideways roughly 10.8% under its high while the target raises finished landing. The narrative leg an investor is buying is unchanged: GLP-1 adoption expands, rather than obsoletes, the addressable market for the behaviour-change and coaching wrap, and Omada is now proving it with operating leverage instead of a story. The open question is the first-ever Investor Day on 2026-09-10, where the GLP-1 prescribing, Flex Care and cholesterol programs — all explicitly excluded from the $334–340M guide — either receive a dated ramp or stay unmodelled for another quarter.

The narrative is maturing. accelerating was the right label through mid-July, when the name was still being discovered: BTIG initiated Buy $30 on 2026-07-17, Citizens raised to $27 on 2026-07-20, and the Investor Day was announced 2026-07-15. Since the print, coverage has broadened rather than deepened — twelve sell-side analysts now carry the name per stockanalysis.com as of 2026-08-21, with an average target of $28.25 — and the flow has moderated: five target actions between 2026-08-03 and 2026-08-14 produced a lower close on 2026-08-21 than the one before them. Well known, still working, thinner marginal bid. Not saturated, because the 2026-09-10 event is undelivered and the largest revenue lines in the story are not yet in any guide.

Bullish and bearish views on Omada Health, Inc.

The model's bull view on Omada Health, Inc. (OMDA), in brief: Operating leverage arrived ahead of the revenue line. The bear view: The upgrade cycle is crowded and the covering houses disagree. Both cases follow in full.

Bull Case

• Operating leverage arrived ahead of the revenue line. Q2 2026 (2026-08-06): adjusted EBITDA $11M versus $(0.2)M in Q2 2025, GAAP gross margin 73% at a quarterly record, GAAP net income $5M. FY adjusted EBITDA is guided $21–27M.
• Two consecutive guidance raises. FY2026 revenue went to $322–330M on 2026-05-07, then $334–340M on 2026-08-06. The August range cleared the $327.789M consensus outright rather than straddling it.
• Member growth has not hit the bear threshold. 1.1 million total members at 2026-06-30, +45% YoY, after 1.025M and +51% at Q1-end. The prior note's deceleration marker — growth falling through roughly 40% — was not tripped.
• Revenue per member is not carrying the growth. TTM revenue per total member of approximately $284 at 2026-06-30, up roughly 2% YoY (Q2 release), so the +43% top line is coming from enrolled lives rather than price. That is the cleaner variable to underwrite into the 2027 employer selling season.
• Financing is off the table. $222M cash and equivalents at 2026-06-30 against a GAAP-profitable quarter. Market capitalisation of $1.46 billion on 61.22 million shares outstanding and TTM revenue of $309.76M, +47.6% (stockanalysis.com, 2026-08-21).
• Guidance still excludes the optionality. GLP-1 prescribing, Flex Care and the cholesterol program contribute nothing material to the $334–340M range by management's own framing, which makes 2026-09-10 the first venue where they get quantified.

Bear Case

• The upgrade cycle is crowded and the covering houses disagree. Barclays Overweight $25 (2026-08-03), BTIG Buy $35 (2026-08-10), Baird Neutral $25 (2026-08-12), JP Morgan Overweight $30 and Citizens Market Outperform $32 (both 2026-08-14). Baird's $25 sits about 5% above the 2026-08-21 close of $23.89; the $25-to-$35 spread is a wide disagreement on terminal value for a company with five public quarters.
• The tape gave the print back. A 52-week high of $26.78 followed by closes of $24.04 on 2026-08-14 and $23.89 on 2026-08-21. Beat-and-raise news that is is a different structure than one that is, and the giveback happened while upgrades were still printing.
• Second-half arithmetic needs checking against the raise. Q1 revenue was $78.0M and Q2 $87.8M; the $334–340M FY range has to be reconciled to those two figures, and a reader should work out whether the implied H2 embeds a step down from Q2's +43% growth rate before paying for continuation.
• Investor Day is two-sided. A first Investor Day is where long-term frameworks get set. If the multi-year growth algorithm presented on 2026-09-10 lands below what a +44.7% three-month move implies, the event resets the model downward without any change in the business.
• A founder handoff sits at the top of the re-rating. Announced 2026-08-06: Wei-Li Shao becomes CEO effective 2027-01-01, Sean Duffy moves to Founder and Executive Chair, Jeri Hilleman becomes Lead Independent Director. Pre-announced and orderly, but the transition lands inside the 2027 selling season.

Setup & Price Structure

• Last completed daily close $23.89 on 2026-08-21; 52-week high $26.78; 10.8% below that high; three-month price change of +44.7%; RSI(14) at 65.1.
• The relevant floor is the mid-July shelf that formed before the print: closes of $23.44 on 2026-07-14 and $23.70 on 2026-07-17. The 2026-08-21 close sits just above it, which means the entire post-print advance has been retraced into the pre-print base without breaking it.
• Above, the reclaim levels are the $25.87 October-2025 pivot and then the $26.78 high. Neither has been retaken since the print.
• RSI at 65.1 while price is 10.8% off the high says the moving averages have caught up to price during the sideways period rather than price extending away from them — the readout is consolidation, not exhaustion, though the two look identical until one resolves.
• Crowding and positioning observables, stated as observables: twelve covering analysts with an average target of $28.25 against a $23.89 close (stockanalysis.com, 2026-08-21); five target revisions inside twelve days ending 2026-08-14; a Form 4 dated 2026-08-12 showing President Wei-Li Shao selling 8,866 shares at $25.0167 under a Rule 10b5-1 plan adopted 2026-03-13, leaving 307,372 shares held directly; 61.22 million shares outstanding, a small float for a June-2025 IPO whose lockup has cleared. No new company filing has been disclosed since 2026-08-14.

Catalyst Calendar (next 30 days)

• 2026-09-10 — First-ever Investor Day, New York City, 1:00pm EDT, live webcast (announced 2026-07-15). The only dated company event inside the window. Long-term targets, and any quantified schedule for GLP-1 prescribing, Flex Care and the cholesterol program, land here or do not.
• ~2026-11-05 (est.) — Q3 2026 results, timing estimated from the 2026-05-07 and 2026-08-06 reporting cadence. Outside the 30-day window; the first hard check on the H2 path implied by the $334–340M guide.
• 2027-01-01 — CEO transition takes effect. Commentary at the Investor Day is the earliest read on how the handoff is being staged.

What Would Change Our Mind

The structure that matters is the pre-print shelf at $23.44–$23.70 from mid-July. Losing it would mean the 2026-08-06 beat, the guidance raise and five target increases produced no durable bid, which is a statement about who is left to buy rather than about the quarter. Concretely: a weekly close below $22 gives back the entire post-print leg and puts price under that shelf. A second, independent break is the 2026-09-10 Investor Day passing without a dated contribution path for GLP-1 prescribing, Flex Care or the cholesterol program — the excluded lines are the reason the name carries a growth multiple, and an Investor Day that leaves them qualitative converts the story back to the guided $334–340M business. On the other side, a weekly close above $25.87 that holds would say the consolidation resolved upward and the label stays maturing rather than rolling toward saturated. A Q3 print (est. ~2026-11-05) implying a sequential decline against Q2's $87.8M would break the continuation case regardless of where price sits.

Correlation Notes

• GLP-1 complex. Omada trades as a second-order expression of GLP-1 adoption; sentiment shifts in the obesity-drug names and in payer coverage decisions for GLP-1s propagate here without touching Omada's own numbers. The company's framing is that prescribing volume expands the wrap-around market; a payer pullback on GLP-1 coverage would test that directly.
• Digital-health and virtual-care cohort. Multiple compression across employer-benefit and virtual-care peers has historically moved this group together irrespective of individual execution, and Omada's five-quarter public history gives it no separate valuation anchor.
• Employer plan-design cycle. Revenue is contracted through employers and health plans, so the calendar-Q3/Q4 selling season for 2027 is the shared variable across the cohort. Commentary on it at the 2026-09-10 event or the Q3 call is the check.
• Small-float mechanics. 61.22 million shares outstanding (stockanalysis.com, 2026-08-21) against a $1.46 billion market capitalisation means index-flow and single-block events move price disproportionately relative to news flow.